Clinical trial NCT05339724: Platelets in Cystic Fibrosis Lung Inflammation
Official title: Platelets: A Neglected Cell in Cystic Fibrosis Lung Inflammation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Platelet Levels and Mean Platelet Volume in Patients With CF
Keywords: cystic fibrosis, platelet count, mean platelet volume
Lead sponsor: Mersin Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2022-04-21
Enrollment: 53
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Cystic fibrosis patients

Brief summary: Cystic fibrosis (CF) is a chronic multiorgan disorder caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Chronic airway infection by bacterial pathogens accounts for the progressive, suppurative pulmonary disease that leads to significant morbidity and mortality in patients with CF. Neutrophil recruitment to the lungs accounts the most important contributor to pulmonary destruction. However, there is evidence that platelets may also have an important role in the pathogenesis of inflammation. To our knowledge, there is few information in platelet levels in patients with cystic fibrosis during pulmonary exacerbation, chronic airway colonization and when stable.

Detailed description: Airway inflammation in CF is predominantly neutrophilic in nature with increased concentrations of pro-inflammatory mediators include TNF-α, IL-1β, IL-6, IL-8, IL-17, IL-33, GM-CSF and G-CSF. In addition, other cell types including macrophages and T-lymphocytes are expressed by CFTR and contribute to the CF inflammatory response.

Researches have indicated that platelets may also have a significant contribution to the inflammation. Platelet depletion or antiplatelet therapies attenuate injury and mortality in animal models of acute lung injury. More importantly, CFTR expression has been shown on human platelets. Recent data suggests that CF patients have an increase in circulating activated platelets and platelet reactivity.

Taken together, these observations support a potentially important role of platelets in regulating lung inflammation in CF. However, there are few studies examine platelet and lung inflammation interraction in patients with CF. Therefore we aimed to investigate platelet count (PC) and mean platelet volume (MPV) levels in various conditions in our CF patients.

Eligibility criteria: Inclusion Criteria:

* All regularly followed cystic fibrosis patients with clinical and laboratory results could be obtained from medical charts.

Exclusion Criteria:

* None

Primary outcomes:
measure: Platelet levels and mean platelet volume in acute pulmonary infection in patients with cystic fibrosis
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Mersin
country: Turkey
facility: Mersin City Research & Training Hospital
Study officials:
affiliation: Assoc Prof, Mersin City Research & Training Hospital
name: Ali Özdemir, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Clinical Pediatrician, Mersin City Research & Training Hospital
name: Murat Ersoy, MD
role: STUDY_CHAIR
References: